Background {#Sec1}
==========

The use of iron therapy to manage renal anemia in patients with chronic kidney disease (CKD) has increased significantly in recent years \[[@CR1]\], partly in response to concerns about the safety of erythropoiesis-stimulating agent (ESA) therapies \[[@CR2], [@CR3]\]. Randomized trials have shown intravenous (IV) iron therapy to be more effective than oral iron in terms of replenishing depleted iron stores and improving anemia in patients on dialysis \[[@CR4]--[@CR6]\]. In non-dialysis dependent CKD (ND-CKD), trials have confirmed the benefits of IV versus oral iron therapy but have typically been no longer than 8 weeks in duration \[[@CR7]--[@CR11]\]. Recently, the randomized 56-week FIND-CKD study compared IV ferric carboxymaltose (FCM) versus oral iron in patients with ND-CKD, anemia, and iron deficiency not receiving ESA therapy \[[@CR12]\]. Intravenous FCM targeting a ferritin level of 400--600 μg/L delayed and/or reduced the need for other anemia management (including ESAs) significantly at 1 year compared to patients receiving oral iron, and the hematopoietic response was more rapid.

However, concerns exist about the potential renal toxicity of IV iron therapy \[[@CR13]\]. Rapid release of large amounts of iron into the bloodstream could generate 'free' iron in the circulation (non-transferrin bound iron, NTBI) which may promote oxidative stress \[[@CR14], [@CR15]\]. Some IV iron complexes such as ferric gluconate contain weakly-bound iron that is released readily and quickly \[[@CR15]\]. In contrast, animal models have shown, that oxidative stress does not increase with more stable IV iron complexes such as FCM \[[@CR16]--[@CR18]\]. Clinical evidence relating to a possible effect of IV iron therapy on renal function is limited. Single-dose and short-term (5-week) studies from one center have indicated that iron sucrose may induce renal injury mediated by oxidative stress and inflammation \[[@CR19]--[@CR23]\]. However, the recently published REVOKE study, which randomized patients with ND-CKD to IV iron sucrose or oral iron, showed neither a difference in renal function decline (based on GFR measured by iothalamate clearance) nor in proteinuria during follow-up lasting up to 2 years \[[@CR24]\]. Confirmatory data are clearly important.

The FIND-CKD trial included protocol-specified monitoring of renal function in over 600 patients with ND-CKD, based on estimated GFR (eGFR), throughout the 1-year study \[[@CR25]\]. Data were analyzed to compare renal outcomes in patients randomized to IV FCM using two different dosing regimens aiming for different target ferritin concentrations, with those in patients receiving oral iron.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

FIND-CKD was a 56-week, open-label, multicenter, prospective, randomized, three-arm study undertaken during December 2009 to January 2012 at 193 nephrology centers in 20 countries (ClinicalTrials.gov NCT00994318) \[[@CR25]\].

Patient population {#Sec4}
------------------

Adult patients (≥18 years) with ND-CKD were eligible for inclusion if (a) at least one Hb level was between 9 and 11 g/dL within 4 weeks of randomization, (b) any ferritin level was \<100 μg/L, or \<200 μg/L with transferrin saturation (TSAT) \<20%, within 4 weeks of randomization, (c) eGFR was ≤60 mL/min/1.73 m^2^ (four-variable Modification of Diet in Renal Disease \[MDRD-4\] equation \[[@CR26]\]), the prior rate of eGFR loss was ≤12 mL/min/1.73 m^2^/year and predicted eGFR at 12 months based on previous decline was ≥15 mL/min/1.73 m^2^, and (d) no ESA had been administered within 4 months prior to randomization. Estimates of prior eGFR loss were based on at least two values over at least 4 weeks prior to randomization, and preferably three values over at least 3 months.

Key exclusion criteria included current dialysis, anticipated dialysis or transplantation during the study, anemia due to reasons other than iron deficiency, a documented history of discontinuing oral iron products due to significant gastrointestinal distress, known active infection, C-reactive protein \>20 mg/L, overt bleeding, active malignancy, chronic liver disease, concomitant New York Heart Association Class IV heart failure and poorly controlled hypertension (\>160 mmHg systolic pressure or \>100 mmHg diastolic pressure).

Randomization and intervention {#Sec5}
------------------------------

Eligible patients were randomized centrally via a central interactive voice-response system in a 1:1:2 ratio to high ferritin FCM, low ferritin FCM or oral iron. The dose of FCM (Ferinject^®^, Vifor International, St Gallen, Switzerland) in the high ferritin and low ferritin FCM groups was adjusted to target a ferritin level of 400−600 μg/L and 100--200 μg/L, respectively. An initial single dose was administered on day 0: 1000 mg iron as FCM in the high ferritin FCM group (500 mg iron on days 0 and 7 in patients weighing ≤66 kg) and 200 mg iron as FCM in the low ferritin FCM group if ferritin was \<100 μg/L. During weeks 4 to 48, FCM was administered every 4 weeks in the high ferritin FCM group at a dose of 500 mg iron if ferritin was in the range 200 to \<400 μg/L, and at a dose of 1000 mg iron if ferritin was \<200 μg/L, and in the low ferritin FCM group at a dose of 200 mg iron if ferritin was \<100 μg/L. In both groups, dosing was withheld if TSAT was ≥40%. Oral iron therapy consisted of commercially-available ferrous sulfate at a dose of 304 mg (100 mg of iron) twice daily to week 52. During the first 8 weeks after randomization, patients were not to receive ESAs, blood transfusion or any anemia therapy other than study drug unless there was an absolute requirement, after which ESAs and other therapies were permitted according to local practice if the Hb was \<10 g/dL.

Assessment of renal function {#Sec6}
----------------------------

Renal function was assessed by eGFR, with values calculated locally and provided by the study sites using the MDRD-4 formula \[[@CR26]\]. Estimated GFR was recorded at baseline and at every 3 months throughout the 12-month study period. The change in eGFR from baseline to the end of the study was a pre-specified secondary endpoint of the trial. GFR was estimated by the MDRD-4 formula \[[@CR26]\]. As a *post hoc* sensitivity analysis, GFR was also estimated by the creatinine-based Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula \[[@CR27]\]. CKD-EPI values were calculated centrally using locally-measured serum creatinine levels. The percentage of patients starting dialysis was a further pre-specified secondary endpoint.

Statistical analysis {#Sec7}
--------------------

All analyses of renal function were exploratory. Analysis of covariance (ANCOVA) modeling was used to compare the change in eGFR values from baseline to month 12 between groups based on least square (LS) mean values using a repeated fixed effects model with treatment, visit and pooled country as factors, baseline eGFR as covariate, and treatment-by-visit as an interaction. Change in eGFR at month 12 was summarized in subpopulations of patients according to age (≤ or \> median), gender, body mass index (BMI, ≤ or \> median), baseline systolic and diastolic blood pressure (≤ or \> median), mean arterial pressure and history of diabetes at baseline. Furthermore, a multivariate analysis including demographics and baseline characteristics (age, gender, BMI, systolic and diastolic blood pressure, diabetic status, prior use of angiotensin converting enzyme \[ACE\] inhibitor and angiotensin II receptor blocker \[ARB\] medications) was performed to check for potential confounding effect and best impacting factor on the analysis of treatment effect.

For the proportion of patients requiring dialysis, logistic regression analyses were performed and odds ratios (ORs) were used to compare treatment groups.

*Post hoc*, absolute eGFR values and the change in eGFR from baseline to month 12 were analyzed according to (i) quartiles of total FCM dose throughout the 12-month study using pooled data from both FCM treatment groups (ii) quartiles of change in ferritin level from baseline to month 12 across all patients (iii) quartiles of change in TSAT level from baseline to month 12 across all patients.

Renal function was analyzed in the intention-to-treat (ITT) population, comprising all patients who received at least one dose of randomized treatment and who attended at least one post-baseline visit. Patients were excluded from the analysis of change in eGFR to month 12 if (a) they reached the primary event before month 12 (i.e. received alternative management for anemia) or (b) the randomized treatment regimen was permanently discontinued before month 12. Within this cohort, calculations for the change in eGFR, ferritin and TSAT from baseline to month 12 were based on the subpopulations of patients who had values available at both time points.

Adverse events were analyzed in the safety population, comprising all patients who received at least one dose of randomized study drug.

All statistical analyses were performed using SAS Version 9.3 (SAS Institute Inc. SAS/STAT, Cary, NC, USA).

Results {#Sec8}
=======

Study population {#Sec9}
----------------

In total, 613 patients were randomized and included in the ITT population. Estimated GFR was measured at baseline in all patients. Of 519 patients who completed the study, 166 patients had started another anemia management and/or stopped the randomized study regimen before month 12, and were excluded from analyses. Thus eGFR values at both baseline and month 12 were analyzed in 353 patients (97, 89 and 167 patients in the high ferritin FCM group, the low ferritin FCM group and the oral iron group, respectively). These patients were included in the current analysis. The demographics and other characteristics of this subpopulation (Table [1](#Tab1){ref-type="table"}) did not differ from the total ITT population (Additional file [1](#MOESM1){ref-type="media"}: Table S1) and were comparable between groups.Table 1Baseline characteristics for patients with eGFR values at baseline and month 12High ferritin FCM (*n* = 97)Low ferritin FCM (*n* = 89)Oral iron\
(*n* = 167)Age, years69.3 (12.9)69.0 (12.1)69.6 (12.7)Female gender, n (%)61 ((62.9)56 (62.9)106 (63.5)White race, n (%)93 (95.9)83 (93.3)159 (95.2)Body mass index, kg/m^2^30.5 (6.8)30.0 (5.3)29.4 (5.4)History of diabetes, n (%)61 (62.9)59 (66.3)106 (63.5)Endogenous erythropoietin, mIU/mL29.4 (24.6)29.6 (27.4)26.3 (20.9)Hb, g/dL10.4 (0.7)10.5 (0.9)10.7 (0.6)Ferritin, μg/L54.2 94.9)45.8 (44.3)52.4 (39.9)TSAT, %16.3 (20.2)14.9 (7.5)14.8 (7.0)C-reactive protein, mg/L7.4 (13.4)5.7 (5.9)5.3 (6.5)ACE inhibitor therapy prior to study entry, n (%)^a^32 (33.0)37 (41.6)69 (41.3)Angiotensin II antagonist therapy prior to study entry, n (%)^b^41 (42.3)33 (37.1)77 (46.1)Continuous variables are shown as mean (SD)*ACE* angiotensin converting enzyme inhibitor, *FCM* ferric carboxymaltose, *Hb* hemoglobin, *TSAT* transferrin saturation^a^Includes patients receiving ACE inhibitor combinations^b^Includes patients receiving angiotensin II antagonist combinations

Baseline eGFR in this subpopulation of patients was similar between treatment groups (Table [2](#Tab2){ref-type="table"}) and did not show any relevant differences to baseline values in the total ITT population (mean \[SD\] 32.8 \[11.7\] mL/min/1.73 m^2^, 31.5 \[10.7\] mL/min/1.73m^2^and 32.3 \[11.6\] mL/min/1.73 m^2^, respectively, in the high ferritin FCM, low ferritin FCM and oral iron groups).Table 2Estimated GFR (eGFR) for patients with eGFR values at baseline and month 12High ferritin FCM (*n* = 97)Low ferritin FCM (*n* = 89)Oral iron (*n* = 167)eGFR at baseline (MDRD), mL/min/1.73 m^2^ Mean (SD)34.9 (11.3)32.8 (10.8)34.2 (12.3) ≥ 60, n (%)1 (1.0)1 (1.1)3 (1.8) 30 to \<60, n (%)62 (63.9)51 (57.3)101 (60.5) 15 to \<30, n (%)34 (35.1)37 (41.6)60 (35.9) \< 15, n (%)003 (1.8)eGFR at month 12 (MDRD), mL/min/1.73 m^2^ Mean (SD)35.6 (13.8)32.1 (12.7)33.4 (14.5) ≥ 60, n (%)7 (7.2)4 (4.5)7 (4.2) 30 to \<60, n (%)54 (55.7)40 (44.9)83 (49.7) 15 to \<30, n (%)32 (33.0)39 (43.8)65 (38.9) \< 15, n (%)4 (4.1)6 (6.7)12 (7.2)Change from baseline to month 12, LS mean (SE) (MDRD), mL/min/1.73 m^2^0.7 (0.9)-0.9 (0.9)-0.9 (0.7)  *p* value for change vs oral iron^a^0.150.99ReferenceRelative change from baseline to month 12, LS mean (SE) (MDRD), %3.1 (2.6)-2.4 (2.7)-2.2 (2.0)  *p* value for change vs oral iron^a^0.0980.95ReferenceeGFR (CKD-EPI) mL/min/1.73 m^2^*n* = 82*n* = 68*n* = 137 Mean (SD) at baseline33.5 (11.9)32.0 (11.8)32.5 (13.4) Mean (SD) at month 1234.8 (13.1)31.1 (13.5)31.0 (14.8) Change, LS mean (SE), mL/min/1.73 m^2^1.3 (1.0)-1.2 (1.0)-1.7 (0.7)  *p* value for change vs oral iron^a^0.0120.68ReferenceeGFR was estimated by the MDRD-4 equation \[[@CR27]\] at the local laboratory*CI* confidence interval, *CKD-EPI* Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), *eGFR* estimated GFR, *FCM* ferric carboxymaltose, *LS* least squares, *MDRD* Modification of Diet in Renal Disease, *SE* standard error^a^Analysis of covariance analysis based on least square mean values, using repeated measures

Four patients in this cohort of 353 patients were included against protocol with baseline eGFR \>60 mL/min/1.73 m^2^: one high ferritin FCM patient (63 mL/min/1.73 m^2^), one low ferritin FCM patient (61 mL/min/1.73 m^2^) and two patients in the oral iron group (66 and 77 mL/min/1.73 m^2^). Three patients in the oral iron group contravened the exclusion criterion that eGFR loss was to be no more than 12 mL/min/1.73 m^2^ per year.

Change in renal function {#Sec10}
------------------------

Values for eGFR showed no change in any of the three treatment groups throughout the 12-month study (Fig. [1](#Fig1){ref-type="fig"}). At month 12, mean (SD) eGFR was 35.6 (13.8) mL/min/1.73 m^2^, 32.1 (12.7) mL/min/1.73 m^2^ and 33.4 (14.5) mL/min/1.73 m^2^, respectively. The pre-defined endpoint of change from baseline to month 12 was +0.7 (0.9) mL/min/1.73 m^2^ in the high ferritin FCM group, -0.9 (0.9) mL/min/1.73 m^2^ in the low ferritin FCM group and -0.9 (0.7) mL/min/1.73 m^2^ in the oral iron group (least square \[LS\] mean \[SE\] values). There were no significant differences in the change from baseline to month 12 for either FCM group versus oral iron (*p* = 0.15 for the high ferritin group, *p* = 0.99 for the low ferritin FCM group). The mean (SE) percentage change in eGFR was 3.1 (2.6)% in the high ferritin FCM group (*p* = 0.098 versus oral iron) (Table [2](#Tab2){ref-type="table"}).Fig. 1Estimated GFR to month 12 according to treatment group in patients with eGFR values at baseline and month 12. Values are shown as mean (SD). FCM, ferric carboxymaltose; eGFR, estimated GFR

As a sensitivity analysis, eGFR was also calculated using the CKD-EPI formula. Serum creatinine values were provided for central calculation of CKD-EPI values in 82, 68 and 137 patients in the high ferritin FCM, low ferritin FCM and oral iron groups, respectively. Based on the CKD-EPI formula, there was a significant increase in eGFR from baseline to month 12 for the high ferritin FCM group versus oral iron (*p* = 0.012) (Table [2](#Tab2){ref-type="table"}).

When the change in eGFR from baseline to month 12 was assessed in subpopulations of patients according to age, gender, BMI, presence/absence of diabetes, systolic and diastolic blood pressure and mean arterial pressure, no apparent influence of treatment group was observed (Additional file [2](#MOESM2){ref-type="media"}: Table [2](#Tab2){ref-type="table"}).

Change in renal function according to FCM dose {#Sec11}
----------------------------------------------

The mean (SD) total dose of FCM 2793 (932) mg iron in the high ferritin group and 1205 (626) mg iron in the low ferritin group among patients with eGFR data available at baseline and month 12 (excluding patients who started another anemia therapy or permanently discontinued study treatment.) The change in eGFR from baseline to month 12 showed no association with total FCM dose when plotted individually for patients in either the high ferritin FCM or low ferritin FCM groups (Additional file [3](#MOESM3){ref-type="media"}: Figure S1). Using pooled data from both FCM groups, the change in eGFR to month 12 was analyzed by quartiles of total FCM dose (Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2Absolute estimated glomerular filtration rate (eGFR) and change in eGFR from baseline to month 12 according to quartiles of (**a**) total ferric carboxymaltose (FCM) dose to month 12 in patients randomized to high ferritin FCM or low ferritin FCM (**b**) change in ferritin from baseline to month 12 across all treatment groups and (**c**) change in transferrin saturation (TSAT) from baseline at month 12 across all treatment groups. Data are shown for patients with eGFR values at baseline and month 12. Change in eGFR is shown as least squares (LS) mean values. MDRD, Modification of Diet in Renal Disease

The multivariate model indicated that age (*p* = 0.007), systolic blood pressure (*p* = 0.004), diabetic status (*p* = 0.058) and prior use of ACE inhibitor therapy (*p* = 0.054) exerted an impact on the change in eGFR (MDRD) to month 12. When these factors were added into the repeated measures model over time, the least square mean values for treatment effect were similar for the high ferritin FCM, low ferritin FCM and oral iron groups (0.7, -0.8 and -0.9 mL/min/1.73 m^2^, respectively; *p* = 0.14 for high ferritin FCM versus oral iron, *p* = 0.92 for low ferritin FCM versus oral iron). When repeated using the CKD-EPI equation to estimate GFR, only age (*p* = 0.042) and systolic blood pressure (*p* = 0.004) were found to influence the change in eGFR to month 12. Inclusion of these two factors in the repeated measure model produced LS mean values of 1.3 mL/min/1.73 m^2^ for the high ferritin FCM group, -1.1 mL/min/1.73 m^2^ for the low ferritin FCM group and -1.7 mL/min/1.73 m^2^ for the oral iron group (*p* = 0.010 versus high ferritin FCM, *p* = 0.613 versus low ferritin FCM).

Change in renal function according to iron status {#Sec12}
-------------------------------------------------

Mean ferritin levels were within the pre-specified target ranges from week 12 to the end of the study in both of the FCM treatment arms (Additional file [4](#MOESM4){ref-type="media"}: Figure S2a). At month 12, the mean (SD) change in ferritin from baseline was 455 (116), 81 (59) and 139 (111) μg/L in the high ferritin FCM, low ferritin FCM and oral iron groups, respectively, among patients with eGFR available at baseline and month 12. The change in eGFR from baseline to month 12 showed no significant association with the change in ferritin over the same period when analyzed by quartiles (Fig. [2b](#Fig2){ref-type="fig"}).

TSAT levels to month 12 are shown in Additional file [4](#MOESM4){ref-type="media"}: Figure S2b. As observed for ferritin levels, the change in eGFR showed no significant differences between quartiles of change in TSAT (Fig. [2c](#Fig2){ref-type="fig"}).

Renal events {#Sec13}
------------

In total, 16/613 patients in the ITT population (2.6%) progressed to dialysis by month 12 (5 high ferritin FCM, 1 low ferritin FCM, 10 oral iron). There was no significant difference in the risk of dialysis for either FCM group versus oral iron: OR 1.01 (95% CI 0.34, 3.00; *p* = 0.99) for the high ferritin FCM group and OR 0.20 (95% CI 0.03, 1.56; *p* = 0.12) for the low ferritin group. No patient underwent renal transplantation.

Rates of adverse events and serious adverse events related to renal function were low with no indication of clinically relevant differences between treatment groups (Additional file [5](#MOESM5){ref-type="media"}: Table S3).

Discussion {#Sec14}
==========

Results from the randomized FIND-CKD trial show that compared to oral iron, administration of IV FCM in doses that maintain ferritin levels of 100--200 μg/L or 400--600 μg/L does not negatively impact renal function, as determined by eGFR, in patients with ND-CKD after 1 year. Mean eGFR remained stable during the study in both the FCM treatment groups, and the change in eGFR to 1 year did not differ from that seen in patients treated with oral iron therapy, either on univariate or multivariate analysis. These findings, calculated using the pre-specified MDRD-4 formula, were confirmed when GFR was estimated by the more recently developed CKD-EPI formula \[[@CR28]\]. Indeed, if anything, there was an increase in eGFR in the patients in the high-ferritin FCM arm compared to oral iron using the CKD-EPI formula (*p* = 0.012) which was confirmed on multivariate analysis. There was no difference between groups in the rate of progression to dialysis and no evidence of increased renal adverse events in either FCM treatment group.

Clinical studies measuring the short- or long-term effect of IV iron complexes on renal function versus controls are relatively scarce. Van Wyck et al. randomized 188 patients with ND-CKD to a total dose of 1000 mg iron as iron sucrose (infused over 3.5--4 h) or oral iron sulfate \[[@CR10]\]. At the end of the 6-week study, there was a mean decrease in eGFR in both treatment arms, but the decrease was smaller in the iron sucrose arm (-1.45 mL/min/1.73 m^2^ versus -4.40 mL/min/1.73 m^2^ in the oral iron arm; *p* = 0.01). McMahon et al. undertook a randomized trial of iron sucrose (100--200 mg every two months) or oral iron sulfate for 12 months in patients with ND-CKD who were non-anemic (Hb ≥11 g/dL) and iron replete (ferritin \>300 μg/L and TSAT \>25%) at baseline, and has described a similar change in eGFR in both treatment groups over the study period \[[@CR29]\]. This similarity was observed despite elevated iron indices in the IV iron group at month 12 (mean ferritin 363 μg/L versus 125 μg/L in the oral iron group; TSAT 30% versus 21%). However, the study analyzed only 85 patients, such that a relatively small effect on renal function may have remained undetected, and the study protocol specified only modest doses of iron supplementation in both the IV and oral iron groups (the actual amount administered was not specified). Lastly, a recent randomized trial of IV iron sucrose versus oral iron showed no change in measured GFR over 2 years' follow-up between the two arms of the study \[[@CR24]\]. Other randomized trials comparing IV iron versus oral iron have not reported renal function, but there was no evidence of a higher rate of renal adverse events in the IV iron groups versus patients receiving oral iron therapy \[[@CR7]--[@CR9], [@CR11]\].

Regarding a possible effect of IV iron on proteinuria, in a blinded, randomized, placebo-controlled cross-over study of eight patients with ND-CKD, Leehey et al. assessed the effect of a single dose of ferric gluconate at a dose of 125 mg iron infused over one hour, or 250 mg iron over two hours \[[@CR21]\]. They observed no evidence of acute renal injury, as assessed by albuminuria, proteinuria or enzymuria, although plasma levels of the oxidative stress marker malondialdehyde (MDA) increased with both doses. Another randomized trial, by Agarwal and colleagues, administered a single dose of 100 mg iron sucrose to 20 subjects with CKD stage 3 or 4, and also found an increase in MDA versus controls, accompanied by transient proteinuria and enzymuria which resolved within 24 h \[[@CR22]\]. Similar analyses have been performed in repeated dose studies. In a multicenter, randomized trial, 62 patients with ND-CKD and iron deficiency anemia received a weekly dose of either iron sucrose or ferric gluconate (100 mg) for 5 weeks \[[@CR19]\]. Basal levels of proteinuria were similar, but increased post-dosing, with a greater increase with iron sucrose than ferric gluconate \[[@CR19]\]. This was consistent with results from an earlier single-dose study from the same group which showed that a single dose of iron sucrose (100 mg) provoked a significantly higher urinary protein to creatinine ratio than ferric gluconate \[[@CR20]\]. The difference between iron sucrose and ferric gluconate is somewhat unexpected, since the latter is considered to be less stable. Other authors have reported that rapid infusion (5 min) of iron dextran or iron sucrose results in generation of reactive oxygen species \[[@CR15]\], whereas a study of 20 iron-replete dialysis patients found that slow infusion (60 min) of these preparations did not affect biomarkers of oxidative stress or inflammation \[[@CR30]\] (neither study measured renal function). Finally, in the prospective REVOKE trial \[[@CR24]\], which was designed to detect renal toxicity of IV iron, proteinuria was similar in the IV iron sucrose and oral iron arms.

In the current study, FCM-treated patients received an initial single dose of up to 1000 mg iron in the high ferritin group, or 200 mg in the low ferritin group (each infused over 15 min), with mean total doses of \~2800 mg iron and \~1200 mg iron, respectively, among patients with eGFR data available at baseline and month 12. A *post hoc* analysis indicated that within this range, there was no association between quartiles of FCM dose and the change in eGFR during the 12 months after the start of FCM therapy. Moreover, neither absolute levels of ferritin (a marker for iron stores) nor TSAT (a marker for iron availability) at month 12, nor the change in ferritin or TSAT during the study, showed an association with change in eGFR. Thus, the significant increase in ferritin levels achieved in the cohort of patients randomized to high ferritin FCM was not associated with a change in renal function.

Conclusions {#Sec15}
===========

The main limitation of these findings is the 1-year duration of the FIND-CKD trial which, while longer than most previous comparative studies of IV versus oral iron \[[@CR7]--[@CR11], [@CR24]\], may not be adequate to detect a long-term effect on renal function. Within the full study cohort, we restricted the analysis to the patients who remained on the randomized study drug for the full 12-month study; any patient in whom another anemia therapy was introduced or who discontinued the study prematurely was excluded. While this reduced the population size, we believe that this was the most rigorous analytical approach. No patient discontinued the study due to decreasing renal function so bias due to selective discontinuation can be ruled out. Moreover, baseline and month 12 values for eGFR (and the extent of change from baseline to month 12) were similar in each treatment group to those seen in the full ITT population \[[@CR25]\]. A *post hoc* repeated measured modeling calculation showed that the population analyzed here (*n* = 353) had a 15 and 18% power, respectively, to detect a difference of 1.0 ml/min/1.73 m^2^ in the change in eGFR between the high and low ferritin FCM groups, and between the high ferritin FCM and oral iron groups (40 and 49%, respectively, to detect a difference of 2 mL/min/1.73 m^2^). The study used eGFR as the indicator of renal function rather than a method to measure GFR. Furthermore, GFR estimates were based on locally determined serum creatinine values, so that variability between methods at different sites cannot be excluded. It is unlikely, however, that such variations would have obscured differences between treatment groups, since each patient served as their own control at baseline using the same assay. Another limitation is that urinary protein excretion and biomarkers of renal tubular toxicity were not recorded. Also, patients previously showing a rapidly progressive loss of renal function at screening were excluded from the study. Indeed, it is remarkable that the annual loss of eGFR was no more than 1.6 mL/min/1.73^2^ in any group. Other eligibility criteria for the study may have contributed to this stability, notably exclusion of patients with previous eGFR loss \>12 mL/min/1.73 m^2^/year but also, for example, those with poorly controlled hypertension. Moreover, approximately three-quarters of patients were receiving an ACE inhibitor or an angiotensin II receptor antagonist. Lastly, in terms of the study design, the absence of a placebo arm precludes a comparison of renal function using IV iron versus no treatment and would have contributed to understanding if the observed stability of renal function was partly a trial effect.

In conclusion, results from this study indicate a lack of renal toxicity of IV iron therapy in patients with relatively stable renal function. It is important to note that these results do not necessarily apply to other IV iron preparations, due to varying molecular structures and physiochemical properties, or to patients with other characteristics (for example those receiving dialysis). Assessment of longer-term effects of IV iron, however, is required.

Appendix 1 {#Sec16}
==========

The FIND-CKD Investigators {#Sec17}
--------------------------
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Table 3FIND-CKD trial: Ethics Committee approvalsCountrySite NrEthic CommitteeAustralia0101Bellberry HREC 229 Greenhill Road Dulwich SA 5O65Australia0102Bellberry HREC 229 Greenhill Road Dulwich SA 5O65Australia0103Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 23O5Australia0104Research Ethics Committee Royal Adelaide Hospital North Terrace\
Adelaide SA 5OOOAustralia0105Human Research Ethics Committee Royal Melbourne Hospital Parkville, Victoria 3O5OAustralia0106Eastern Health HREC Level 2, 5 Arnold Street Box Hill, Victoria 3f28Australia0106Eastern Health HREC Level 2, 5 Arnold Street Box Hill, Victoria 3f29Australia0107Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 23O5Australia0108PAH Human Research Ethics Committee Tafe 3, Level 2, Bldg 35\
Princess Alexandra Hospital Ispswich Road Woolloongabba, QLD 4fO2Australia9Ballarat Health Services and St. John of God Health Care Ethics Committee\
Base Hospital Drummond Street North PO Box 577 Ballarat 3353Australia0110Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 2305Australia0111Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 2306Australia0111Royal Brisbane and Women's Hospital HREC University of Queensland, Centre for Clinical Research, Level 4, RBWH HERSTON, QUEENSLAND AUSTRALIA 4029Australia0112Sir Charles Gairdner HREC Level 2, A block Hospital Avenue Nedlands, WA 6009Australia0113Royal Perth Hospital HREC Colonial House Wellington Street, WA 6000Australia0114Southern Health HREC 246 Clayton Road Clayton, Victoria 3168Australia0115Sir Charles Gairdner HREC Level 2, A block Hospital Avenue Nedlands, WA 6009Australia0117Cairns Base Hospital Ethics Committee PO Box 902 Cairns, QLD 4870Australia0118Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 2305Australia0119Hunter Area Research Ethics Committee John Hunter Hospital Lookout Road\
New Lambton Heights NSW 2305Australia0120Sir Charles Gairdner HREC Level 2, A block Hospital Avenue Nedlands, WA 6009Austria0202Ethikkommission der Stadt Wien Town Thomas-Klestil-Platz 8/2 A-1030 Wien, OsterreichAustria0203Ethikkommission der Stadt Wien Town Thomas-Klestil-Platz 8/2 A-1030 Wien, OsterreichAustria0204Ethikkommission des Landes Vorarlberg\
Rathausstrassed 15\
A-6900 Bregenz\
OsterreichAustria0205Ethikkommission Krankenhaus der Elisabethinen Linz GmbH Fadingerstrasse 1\
A-4 Linz OsterreichAustria0206Ethikkommission der Medizinischen Universitat Innsbruck Innrain 43\
A-6020 Innsbruck OsterreichAustria0207EK des Landes Oberosterreich Landesnervenklinik Wagner-Jauregg Strasse Wagner-Jauregg Weg 15\
A-4020 Linz OsterreichBelgium0301Secretariaat Ethische Commissie UZ Gent Attn. Prof. Dr Matthys De Pintelaan 185\
9000 GentBelgium0302H.-Hartziekenhuis Roeselare-Menen vzw Attn. Dr. Ludo Marcelis WILGENSTRAAT 2\
8800 ROESELAREBelgium0303Dr Van Vlem\
Onze-Lieve-Vrouwziekenhuis Attn. Greet de Geest Moorselbaan 164 9300 AalstBelgium0304Commissie Medische Ethiek van Universitaire Ziekenhuizen K.U.Leuven Attn. Prof. Walter Van den Bogaert\
Campus Gasthuisberg E330 Herestraat 49 B-3000 LeuvenBelgium0305Kristien Schoenmakers gang beheer en directie ZOL Campus St Jan Schiepse bos 6 3600 GenkBelgium0306Hopitaux IRIS Sud-site Joseph Bracops Rue Dr Huet 79 Brussels 1070Belgium0307Comité d'Ethique du Epicura Ath-Baudour Attn. Dr Frederic Debelle\
136 rue Louis Caty 7331 BaudourBelgium0308Commission d'Ethique Biomédicale Hospitalo- Facultaire Attn. Pr Jean-Marie Maloteaux Cliniques Universitaires Saint-Luc Avenue Hippocrate 55/14 B-1200 BruxellesBelgium0309Comite d'Ethique Hospitalo-Facultaire Universitaire de Liege Centre Hospitalier Universitaire du Sart Tilman, B35 4000 Sart Tilman par Liege 1Belgium0311Centre Hospitalier Universitaire Brugman Attn. Valsamis Joseph\
Place A. Van Gehuchten, 4 1020 Bruxelles \--2Belgium0312Comite d'Ethique Clinique Universitaire de Bruxelles\
Hopital Erasme Route de Lennik 808 1070 Bruxelles - 7Czech Republic0401Etická komise IKEM a FN Thomayerovy s poliklinikou\
Vídeňská 800 140 59 Praha 4Czech Republic0402Etická komise pro multicentrická hodnocení Fakultní nemocnice v Motole V Úvalu 84, 150 06 Praha 5Czech Republic0403Etická komise Litomyšlská nemocnice\
a.s. J. E. Purkyně 652 570 14 LitomyšlCzech Republic0404Etická komise Nemocnice Jihlava Vrchlického 59 586 01 JihlavaCzech Republic0405Etická komise pro multicentrická hodnocení Fakultní nemocnice v Motole V Úvalu 84, 150 06 Praha 5Czech Republic0406Etická komise\
Krajská nemocnice T. Bati a.s. Zlín Havlíčkovo nábřeží 600 762 75 ZlínCzech Republic0407Etická komise Fakultní nemocnice Hradec Králové Sokolská 581500 05 Hradec KrálovéCzech Republic0408Etická Komise Nemocnice Písek, a.s. Karla Čapka 589 397 23 PísekCzech Republic0409Etická komise Nemocnice Tábor, a.s. Kpt. Jaroše 2000 390 03 TáborCzech Republic0410Etická komise\
Nemocnice ve Frýdku-Místku, p.o. El. Krásnohorské 321 738 18 Frýdek-MístekCzech Republic0411Etická komise\
FN Brno Bohunice Jihlavská 20 625 00 BrnoCzech Republic0412Etická komise B. Braun Avitum Bulovka Budínova 67 181 02 Praha 8Czech Republic0413Etická komise B. Braun Avitum Bulovka Budínova 67 181 02 Praha 8Czech Republic0414Etická komise Nemocnice s poliklinikou v Novém Jičíně, p.o.\
K Nemocnici 775/76 741 01 Nový JičínCzech Republic0415Etická komise B. Braun Avitum Bulovka Budínova 67 181 02 Praha 8Czech Republic0416Etická komise Nemocnice Znojmo MUDr. Jana Janského 11 669 02 ZnojmoCzech Republic0417Etická komise B. Braun Avitum Bulovka Budínova 67 181 02 Praha 8Czech Republic0418Etická komise společnosti Fresenius Medical Care - DS, s.r.o.\
Lužná 591\
160 05 Praha 6Czech Republic0419Etická komise pro multicentrická hodnocení Fakultní nemocnice v Motole V Úvalu 84\
150 06 Praha 5Czech Republic0420Etická komise společnosti Fresenius Medical Care - DS, s.r.o.\
Lužná 591\
160 05 Praha 6Czech Republic0421Etická komise společnosti Fresenius Medical Care - DS, s.r.o.\
Lužná 591\
160 05 Praha 6Czech Republic0422Etická komise společnosti Fresenius Medical Care - DS, s.r.o.\
Lužná 591\
160 05 Praha 6Czech Republic0423Etická komise společnosti Fresenius Medical Care - DS, s.r.o.\
Lužná 591\
160 05 Praha 6Czech Republic0424Etická komise pro multicentrická hodnocení Fakultní nemocnice v Motole V Úvalu 84, 150 06 Praha 5Denmark0501De Videnskabsetiske Komiteer for Region\
Hovedstaden\
Regionsgarden\
Kongesn Vaenge\
CK-3400 HillerodDenmark0502De Videnskabsetiske Komiteer for Region\
Hovedstaden\
Regionsgarden\
Kongesn Vaenge\
CK-3400 HillerodDenmark0503De Videnskabsetiske Komiteer for Region Hovedstaden\
Regionsgården Kongens Vænge 2 DK-3400 HillerødDenmark0504De Videnskabsetiske Komiteer for Region\
Hovedstaden\
Regionsgarden\
Kongesn Vaenge\
CK-3400 HillerodFrance0601CPP Sud-Méditerranée IV\
Dr Alain DUBOIS\
Hopital Saint Eloi\
Rue Bertin Sand\
34295 Montpellier\
Cedex 5France0601CPP Sud-Méditerranée IV\
Dr Alain DUBOIS\
Hopital Saint Eloi\
Rue Bertin Sand\
34295 Montpellier\
Cedex 5France0602CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0603CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0604CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0605CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0606CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0607CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0608CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0609CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0610CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0611CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5France0612CPP Sud-Méditerranée IV Dr Alain DUBOIS Hôpital Saint Eloi Rue Bertin Sans 34295 Montpellier Cedex 5Germany0701Ethik-Kommmission bei der Medizinischen Fakultät der Universitat Wurzburg Institut für Pharmakologie und Toxikologie Versbacher Str. 9\
97078 Wurzburg WuerzburgGermany0702Site 0702\
Ethik-Kommission der Arztekammer Hamburg\
Humboldtstr. 67a 22083 HamburgGermany0703Site 0703\
Wthikkommission an der Medizinischen Fakultat Ernst-Moritz-Arndt-Universitat Greifswald Institut fur Pharmakologie\
Friedrich-Loeffler-Str. 23d 17487 GreifswaldGermany0704Site 0704, 0721\
Ethikkommission der Arztekammer Nordrhein Tersteegenstr. 9\
40474 DusseldorfGermany0705Site 0705, 0708, 0710, 0711\
Ethikkommission der Arztekammer Westfalen-Lippe und der Medizinischen Fakultat der WWU-Munster Von-Esmarch-Strasse 62\
48149 MunsterGermany0706Site 0706\
Ethikkommission der Universitat Ulm Helmholtzstrasse 20\
(Oberer Eselsberg) 89081 UlmGermany0708Site 0705, 0708, 0710, 0711\
Ethikkommission der Arztekammer Westfalen-Lippe und der Medizinischen Fakultat der WWU-Munster Von-Esmarch-Strasse 62\
48149 MunsterGermany0709Site 0709, 0729\
Ethik-Kommission der Landesarztekammer Hessen Im Vogelsang 3\
60488 Frankfurt am MainGermany0710Site 0705, 0708, 0710, 0711\
Ethikkommission der Arztekammer Westfalen-Lippe und der Medizinischen Fakultat der WWU-Munster Von-Esmarch-Strasse 62\
48149 MunsterGermany0711Site 0705, 0708, 0710, 0711\
Ethikkommission der Arztekammer Westfalen-Lippe und der Medizinischen Fakultat der WWU-Munster Von-Esmarch-Strasse 62\
48149 MunsterGermany0712Site 0712, 0726\
Ethik-Kommission der Bayerischen Landesarztekammer Muhlbaurstrasse 16 81677 MunchenGermany0713Site 0713, 0725\
Landesamt fur Gesundheit und Soziales Geschaftsstelle der Ethik-Kommission des Landes Berlin Fehrbelliner Platz 1\
10707 BerlinGermany0714Site 0714, 0722\
Ethikkommission Landesarztekammer Rheinland-Pfalz Deutschhausplatz 3 55116 MainzGermany0715Site 0715\
Ethikkommission an der Med. Fakultat der Rheinischen Friedrich-Wilhelms-Universitat Bonn\
Biomedizinisches Zentrum Sigmund-Freud-Str. 25 53105 BonnGermany0716Site 0716\
Ethik-Kommission des Fachbereichs Medizin der Johann Wolfgang Goethe- Universitat Haus 1 Theodor-Stern-Kai 7\
60590 FrankfurtGermany0717Site 0717, 0730\
Ethik-Kommission bei der Landesarztekammer Baden-Wurttemberg Jahnstr. 40 70597 StuttgartGermany0719Site 0719\
Ethikkommission bei der Arztekammer Niedersachsen zur Beurteilung Medizinischer\
Forschung am Menschen Berliner Allee 20 30175 HannoverGermany0720Site 0720\
Ethikkommission bei der Sachsischen Landesarztekammer Schutzenhohe 16\
99 DresdenGermany0721Site 0704, 0721\
Ethikkommission der Arztekammer Nordrhein Tersteegenstr. 9\
40474 DusseldorfGermany0722Site 0714, 0722\
Ethikkommission Landesarztekammer Rheinland-Pfalz Deutschhausplatz 3 55116 MainzGermany0724Site 0724\
Ethik-Kommission der Otto-von-Guericke- Universitat an der Medizinischen Fakultat Leipziger Str. 44 39120 MagdeburgGermany0725Site 0713, 0725\
Landesamt fur Gesundheit und Soziales Geschaftsstelle der Ethik-Kommission des Landes Berlin Fehrbelliner Platz 1\
10707 BerlinGermany0726Site 0712, 0726\
Ethik-Kommission der Bayerischen\
Landesarztekammer\
Muhlbaurstrasse 16\
81677 MunchenGermany0727Site 0727\
Ethik-Kommission der Universitat Witten/Herdecke Alfred-Herrhausen-Str. 50\
58448 WittenGermany0728Site 0728\
Ethikkommission der Med. Fakultat der\
Universitat zu Koln\
Gebaude 5\
Kerpener Str. 62\
50937 KolnGermany0729Site 0709, 0729\
Ethik-Kommission der Landesarztekammer\
Hessen\
Im Vogelsang 3\
60488 Frankfurt am MainGermany0730Site 0717, 0730\
Ethik-Kommission bei der\
LandesarztekammerBaden-Wurttemberg\
Jahnstr. 40\
70597 StuttgartGermany0731Site 0731\
Ethik-Kommission der Landesarztekammer\
Brandenburg\
Dreifertstrasse 12\
03044 CottbusGreece0801Ethical Committee\
General University Hospital of Thessaloniki "Papgeorgiou" Thessaloniki Ring Road, Nea Efkarpia Thessaloniki, 56429Greece0802General Hospital of Thessaloniki "Ippokrateion" 49 Konstantinoupoleos st. Thessaloniki, 56442Greece0803ATTIKON General University Hospital of Athens 1 Rimini Str.\
Chaidari, Athens, 12462Greece0804General University Hospital of Alexandroupolis Dragana Alexandroupolis, 68100Greece0805Ethical Commitee\
General University Hospital of Larissa Mezourlo Larissa, 41110Greece0806Ethics Committee\
Achillopoulio General Prefecture Hospital of Volos 134 Polyeri street\
Volos, 38222Greece0807Ethical Commitee\
General Hospital of Rhodes Aghioi Aphostoloi Rhodes, 85100Greece0808Ethical Commitee\
IPPOKRATEION General Hospital of Athens 114 Vas. Sofias Ave Athens, 11526Greece0809Ethical Commitee\
General Hospital of Athens, KORGALENEIO- BENAKEIO Athenasaki Str. 1\
Athens, 11526Greece0810Ethical Commitee\
General Prefecture Hospital of Ioannina, XATZIKOSTA Avv. Makrigianni 1\
Ioannina, 45550Greece0811Ethical Commitee\
General University Hospital of Patras Rio-Patras Street Rios Patras, 16500Greece0812Ethical Commitee\
General University Hospital of Ioannina Stavros Niarchos Avenue Ioannina, 45550Greece0813Ethical Commitee General Hospital of Arta\
A. Zara Str 4 Arta, 47100Greece0815Ethical Commitee\
General Hospital of Peireus "Tzaneio" Zanni & Afendouli Peireus, 18536Greece0817Ethical Commitee\
General Prefecture Hospital of Argos 191 Korinthou Str.\
Argos, 21200Greece0818Ethical Commitee\
LAIKO General Hospital of Athens 17 Aghiou Thomas Str.\
Athens, 11527Greece0819Ethical Commitee\
General Hospital of Mytilene "Vostanio" 48 E. Vostani Str.\
Vestos, 81100Greece0820Ethical Commitee General Hospital of Serres 2nd k of Serres-Drama National Road Serres, 62100Greece0821Ethical Commitee\
KYANOUS STAVROS General Hospital of Athens\
102, Vas Sofias Ave Athens, 11528Greece0822Ethical Commitee\
IASO General Hospital of Athens Cholargos Athens, 11526Greece0823Ethical Commitee\
General Hospital of Athens "Henry Dunant" 107 Messogheion Ave Athens, 11526Italy1001Comitato Etico\
Dell'Azienda Ospedaliera di Lecco Via Dell'Eremo 9/11 Lecco, 23900Italy1002Comitato Etico Locale per la Sperimentazione Clinical Della AUSL 12 di Viareggio Via Aurelia 335\
55045 Lido di Cà Maiore (LC)Italy1003Comitato Etico Dell'Azeinda Ospedaliera Universitaria Della Seconda Univestità degli Studi di Napoli Via Costatinopoli, 104\
80138 NapoliItaly1004Comitato Etico Indipendente dell'Azienda ospedaliero-Univesitaria Policlinico S. Orsola Via Albertoni 15\
40138 BolognaItaly1005Comitato Etico Della ASL TO/2 di Torino Corso Svizzera 185 bis 10149 TorinoItaly1007Comitato di Bioetica della Azienda Ospedali Riuniti di Bergam Largo Barozzi 1\
24128 BergamoItaly1008Comitato Etico ASL di Caserta Via Unità Italiana 28 81100 CasertaItaly1009Comitato Etico Dell'Azienda Ospedaliera Universitaria 'S. Martin' di Genova Largo Rosanna Benzi 10 16132 GenovaItaly1Comitato Etico Della Provincia di Modena Via Largo del Pozzo 71 41124 ModenaItaly1011Comitato Etico ASL CE/1 Di Caserta Via Unità Italiana 28 81100 CasertaItaly1012Comitato Etico Regionale Unico (CERU) AOU Santa Maria della Misericordia Piazzale Santa maria della Misericordia 15 33100 UdineItaly1013Comitato Etico Scientifico Dell'Azienda Ospedaliera Ospedale S. Carlo Borromeo di Milano\
Via Pio II° n° 3 20153 MilanoItaly1014Comitato Bioetico Dell'Azienda Cannizzaro di Catania Via Messina 829\
95126 CataniaItaly1016Comitato Ethico-Scientifico Dell'Azienda Ospedaliera Ospedale Niguara Ca' Granda Di Milano Piazza Ospedale Maggiore n. 3 20162 MilanoItaly1017Comitato Etico Della AUSL RM/H Di Albano Laziale\
Borgo Garibaldi n. 12 00041 Albano Laziale (RM)Italy1018Comitato Etico Dell'Azienda Ospedaliera Pugliese-Ciaccio Di Catanzaro\
Via Vinicio Cortese, 10 88100 CatanzaroItaly1020Comitato Etico Dell'Azienda Ospedaliera Universitaria S. Giovanni Battista di Torino C so Bramante 88/90 10126 TorinoItaly1021Comitato Etico Scientifico Dell'Azienda Ospedaliera Ospedale S. Carlo Borrome di Milano\
Via Pio II°, n°3 20153 MilanoItaly1022Comitato Etico Central Dell'IRCCS Fondazione Salvatore Maugeri Di Pavia Via Salvatore Maugeri 4 27100 PaviaItaly1023Comitato Etico Sperimentazione clinical Medicinali Della AUSL 8 Di Arezzo Via Curtatone 54\
52100 ArezzoItaly1024Comitato Etico\
Azienda Ospedaliera Universitaria Ospedali Riuniti di figgia\
Viale Luigi Pinto 71100 FoggiaItaly1026Comitato di Etica Della ASL di Salerno Via Federico Ricco, 50 84014 Noceria Inferiore (SA)Italy1027Comitato Etico Per le Sperimentazioni Cliniche die Medicinali Della Provincia di Venezia\
Via Don Federico Tosatto 147 30174 VeneziaItaly1028Comitato Etico Della AUSL RM/G di Tivoli Via Tiburtina 22/a 00019 Tivoli (RM)Italy1029Comitato Etico Delle Aziende Sanitarie Dell'Umbria di Perugia\
Via della Rivoluzione 16 Ellera di Corciano (PG) 06070 PerugiaNetherlan ds1101Meander Medical Center, Lichtenberg location Toetsingscommissie Wetenschappelijk Onderzoek\
Secretariat, P&O Room N042 Utrechtseweg 160\
3818 ES Amersfoort The NetherlandsNetherlan ds1102Medical Ethics Review Committee Zuidwest Holland Fonteynenburghlaan 7\
2275 CX VOORBURG\
The NetherlandsNetherlan ds1102Medical Ethics Review Committee Gelre Hospital Albert Schweitzerlaan 31\
7334 DZ Apeldoorn The NetherlandsNetherlan ds1103Medical Ethics Review Committee Gelre Hospital Albert Schweitzerlaan 31\
7334 DZ Apeldoorn The NetherlandsNetherlan ds1104Medical Ethics Review Committee Albert Schweitzer Hospital loc. DW, Postvak 7, kmr. Z 150\
T.a.v. Ms. A. de Graag -- de Vries Albert Schweitzerplaats 25 3318 AT Dordrecht The NetherlandsNetherlan ds1105METc VU Medical Center Medical Faculty, Room H-565 Van der Boerchorststraat 7 1081 BT Amsterdam The NetherlandsNetherlan ds1106Medical Ethics Review Committee Noord- Holland\
Foreest Medical School Nassauplein 10 1815 GM Alkmaar The NetherlandsNorway1201Regional Committees for Medical and Health Research Ethics (REK) REK-Midt\
Bygg for samfunnsmedisin (5 etg) Håkon Jarlsgt. 11, St. Olavs Hospital TrondheimPoland1301Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1302Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1303Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1306Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1309Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1311Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1313Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1314Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1315Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1316Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1318Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1320Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1321Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1322Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1323Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1324Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1326Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1327Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1328Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1329Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1330Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPoland1331Niezależna Komisja Bioetyczna do Spraw Badań Naukowych przy Gdańskim Uniwersytecie Medycznym ul. M. Skłodowskiej-Curie 3a, 80-201 Gdańsk, PolskaPortugal1402CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalPortugal1403CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalPortugal1404CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalPortugal1405CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalPortugal1406CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalPortugal1407CEIC- National Ethics Committee for Clinical Investigation Parque da Saúde de Lisboa- Avenida do Brasil, 53 1749-004 Lisboa- PortugalSpain1501Hospital Universitario Dr Peset de Valencia CEIC, a/a Raquel E. Blesa, C/Juan de Garray 21, 1er Piso Consultas externas, 46017 ValenciaSpain1503Hospital Universitario Dr Peset de Valencia CEIC, a/a Raquel E. Blesa, C/Juan de Garray 21, 1er Piso Consultas externas, 46017 ValenciaSpain1504CEIC Hospital Universitario La Paz(LEC) Paseo de la Castellana, 261, Planta 8a Hospital General, 28046 MadridSpain1505CEIC Fundació Puigvert IUNA (LEC) Agencia de Gestio del Coneixement Cartagena, 340-350 08025 BarcelonaSpain1506CEIC Hospital Universitario General Gregorio Marañón (CEC) CEIC Area 1, C/ dr Esquerdo, 46, 28007 MadridSpain1507Agencia de Ensayos Clinicos - servicio de Farmacia Hospital Clinic de Barcelona, c/ Villarroel, 170 - Sotano, Escalera 6b, 08036 BarcelonaSpain1509CEIC Hospital Universitario de Bellvitge Edificio Consultas Externas. Planta -1, C/ Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, BarcelonaSpain1510CEIC Hospital Universitari Vall d\'Hebron Edifici Institut de Recerca, 2a planta Passeig Vall d'Hebron 119-129, Barcelona 08035Spain1512CEIC Hospital Universitario Fundación de Alcorcón (LEC) C/ Budapest N1, 28922 Alcorcon, MadridSpain1513CEIC Clinica de Asturias\
Hospital Central de Asturias, Celestino Villamil, s/n, 33006 OviedoSpain1514Hopsital Universitario "Reina Sofia" Comite Etico de Ensayos Clinicos, Edificio de Consultas Externas, planta -1, Avda. Menendez Pidal, s/n, 14004 CordobaSpain1515Hospital Torrecardenas CEIC\
Paraje Torrecardenas, s/n, 04009 AlmeriaSpain1516Fundacion Jimenez Diaz CEIC, Avda. Reyes Catolicos, 2, Entrplanta, 28040 MadridSpain1517Hospital Universitario Principe de Asturias CEIC, Ctra. Alcala-Meco s/n, 28805 Alcala de Henares, MadridSpain1518CEIC de Aragon, Avda. Gomez Laguna, 25 planta 11, 50009 ZaragozaSpain1519Hospital Universitario de Puerto Real, Ctra. NaI IV, km. 665, 11510 Puerto Real, CadizSpain1520CEIC Hospital Universitario de Getafe (LEC) Ctra. De Toledo, km. 12500, 28905 Getafe, MadridSpain1521CEIC Hospital Universitario La Princesa, Findacion para la Investigacion Biomedica, C/ Diego de leon, 62, 28006 MadridSpain1522CEIC Hospital Universitario de Girona Josep Trueta (LEC) avda. De Franca s/n, 17007 GironaSpain1523CEIC Parc Salut del Mar (LEC)\
IMIM-Hospital del Mar, Parc de Recerca Biomedica de Barcelona, Doctor Aiguader, 88, 08003 BarcelonaSweden1601Regionala etikprövningsnämnden\
Stockholm FE 289\
Karolinska Institutet\
Stockholm, 17179Sweden1602Regionala etikprövningsnämnden\
Stockholm FE 289\
Karolinska Institutet\
Stockholm, 17179Sweden1603Regionala etikprövningsnämnden\
Stockholm FE 289\
Karolinska Institutet\
Stockholm, 17179Switzerland1701Kantonal Ethikkommission Aargau Departement Gesundheit und Soziales PD Dr. med. Otto Hilfiker Bachstrasse 15\
5001 AarauSwitzerlan d1702Kantonal Ethik-Kommission (KEK) Prof. Dr. med. Robert Maurer Universitätsspital Zürich Sonneggstr. 12 8091 ZürichSwitzerlan d1703Kantonal Ethik-Kommission (KEK) Prof. Dr. med. Robert Maurer Universitätsspital Zürich Sonneggstr. 12 8091 ZürichSwitzerlan d1704Kantonal Ethikkommission Bern (KEK) Prof. Dr. pharm. Nilaus Tüller Postfach 56 3 BernTurkey1801Ankara University Medical Faculty Deanship Clinical Researches Ethics Committee nkara Universitesi Tip Fakultesi Morfoloji Binası 06100 Sihhiye Ankara TurkeyTurkey1802Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1803Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1804Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1804Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1807Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1810Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirTurkey1811Ege University Medical Faculty Clinical Researches Ethics Committee Ege Universitesi Tip Fakultesi; 35100 Bornova IzmirUnited Kingdom1901Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1902Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1903Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1904Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1905Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1906Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1907Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1908Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1909Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1910Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1911Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1912Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1913Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1914Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1915Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1916Health Research Authority\
NRES Committee Riverside REC\
Bristol REC Centre\
Whitefriars, Lewins MeadUnited Kingdom1917Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1918Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1919Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1920Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1921Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1922Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1923Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1924Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1925Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1926Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1927Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1928Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1929Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom19230Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1931Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1932Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTUnited Kingdom1933Health Research Authority NRES Committee Riverside REC Bristol REC Centre\
Level 3, Block B Whitefriars Lewins Mead Bristol, BS 1 2NTRomania2001National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2002National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2003National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2004National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2005National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2006National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaRomania2007National Ethics Committee for Clinical Study of Medicine (Comisia Nationala de Etica pentru Studiul Clinic al Medicamentului) Av. Sanatescu St., No. 48, 1st district, 011478, Bucharest, RomaniaUS2110Salem VA Medical Center IRB Kim Ragsdale, PhD 1970 Roanoke Blvd\
Salem. VA 24153US2113Integreview IRB Valerie Nelson\
3001, South Lamar Blvd Suite 210 Austin, TX 78704US2105Integreview IRB Valerie Nelson\
3001, South Lamar Blvd Suite 210 Austin, TX 78704US2114Temple VA Medical Cener IRB John W Klocek, PhD 1901 Veterans Memorial Drive Temple, TX 76504

Additional files {#Sec19}
================

Additional file 1: Table S1.Baseline characteristics (ITT population). (DOCX 12 kb) Additional file 2: Table S2.Mean (SD) change in estimated GFR (eGFR) from baseline to month 12 for subpopulations of patients with eGFR values both time points. (DOCX 12 kb) Additional file 3: Figure S1.Scatter plot of change in eGFR from baseline to month 12 according to total IV iron dose in patients randomized to either high ferritin or low ferritin FCM for patients with eGFR values at baseline and month 12. The solid line indicates the linear regression for all points. The dotted line indicates 0 i.e. no change. eGFR, estimated glomerular filtration rate; FCM, ferric carboxymaltose. (EPS 1219 kb) Additional file 4: Figure S2.(a) Ferritin and (b) transferrin saturation (TSAT) for patients with eGFR values at baseline and month 12 who did or did not receive alternative anemia therapy or permanently discontinued study therapy before month 12. BL, baseline; FCM, ferric carboxymaltose. (ZIP 456 kb) Additional file 5: Table S3.Selected renal adverse events and serious adverse events (safety population). (DOCX 11 kb)

ACE

:   Angiotensin converting enzyme

ANCOVA

:   Analysis of covariance

ARB

:   Angiotensin II receptor blocker

BMI

:   Body mass index

CKD

:   Chronic kidney disease

CKD-EPI

:   Chronic Kidney Disease Epidemiology Collaboration

eGFR

:   estimated GFR

ESA

:   Erythropoiesis-stimulating agent

FCM

:   Ferric carboxymaltose

ITT

:   Intention-to-treat

IV

:   Intravenous

MDA

:   Malondialdehyde

MDRD

:   Modification of Diet in Renal Disease

ND-CKD

:   Non-dialysis dependent CKD

NTBI

:   Non-transferrin bound iron

TSAT

:   Transferrin saturation
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